scholarly article | Q13442814 |
P50 | author | Faiez Zannad | Q19631268 |
Piotr Ponikowski | Q22114836 | ||
Lars Køber | Q33310611 | ||
Mihai Gheorghiade | Q60059386 | ||
Bertram Pitt | Q63107334 | ||
Gerasimos Filippatos | Q63107352 | ||
Henry Krum | Q82083581 | ||
Peter Kolkhof | Q99567543 | ||
Christina Nowack | Q114291637 | ||
P2093 | author name string | So-Young Kim | |
P2860 | cites work | ??? | Q28267062 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial | Q34751971 | ||
Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? | Q37503827 | ||
Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics | Q37902778 | ||
Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases | Q42716993 | ||
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). | Q43101047 | ||
Eplerenone in patients with systolic heart failure and mild symptoms | Q44272913 | ||
Efficacy of low-dose spironolactone in subjects with resistant hypertension | Q44628337 | ||
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease | Q57911462 | ||
Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? | Q81818284 | ||
2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve | Q83631957 | ||
P433 | issue | 31 | |
P921 | main subject | patient | Q181600 |
heart failure | Q181754 | ||
chronic renal insufficiency | Q736715 | ||
chronic heart failure | Q11829287 | ||
P304 | page(s) | 2453-2463 | |
P577 | publication date | 2013-05-27 | |
P1433 | published in | European Heart Journal | Q2286839 |
P1476 | title | Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial | |
P478 | volume | 34 |
Q33846431 | 30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development |
Q41367679 | A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy |
Q37098407 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease |
Q37720499 | Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy |
Q38208961 | Aldosterone excess and resistant hypertension: investigation and treatment |
Q37594892 | Aldosterone synthase inhibitors in hypertension: current status and future possibilities |
Q38590227 | An update of the blockade of the renin angiotensin aldosterone system in clinical practice |
Q28544460 | Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade |
Q38770500 | Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. |
Q89752475 | Cardiac phenotype in propionic acidemia - Results of an observational monocentric study |
Q52690991 | Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. |
Q26795398 | Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function |
Q58433377 | Corticosteroid Receptors |
Q38737757 | Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure |
Q86454230 | Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria |
Q58712499 | Diabetic nephropathy: newer therapeutic perspectives |
Q38307958 | Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy |
Q38181208 | Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents |
Q91142607 | Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice |
Q57260308 | Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar Adherence Study |
Q38837657 | Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis |
Q90765706 | Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats |
Q26773030 | Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis |
Q38123754 | Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms |
Q38533385 | Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease |
Q57816948 | Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress |
Q38850114 | Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. |
Q38817871 | Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? |
Q38780801 | From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure |
Q38679303 | Future drug discovery in renin-angiotensin-aldosterone system intervention |
Q51273122 | Genomic and rapid effects of aldosterone: what we know and do not know thus far. |
Q38800239 | Global cardiovascular protection in chronic kidney disease |
Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
Q38182010 | Heart failure highlights in 2012-2013. |
Q34019947 | Interfering with mineralocorticoid receptor activation: the past, present, and future |
Q51741442 | Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. |
Q27027792 | Is there a new dawn for selective mineralocorticoid receptor antagonism? |
Q60153626 | Le renouveau attendu des antagonistes du récepteur de l’aldostérone |
Q61455542 | Long-term blockade of the renin–angiotensin system: an adequate evaluation is still needed |
Q38249892 | Management of hyperkalaemia in chronic kidney disease |
Q90470119 | Microalbuminuria and cardiorenal risk: old and new evidence in different populations |
Q43063544 | Mineralocorticoid Receptor Antagonism in AKI: A New Hope? |
Q89958005 | Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists |
Q99567544 | Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy |
Q89454326 | Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice |
Q34162275 | Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial) |
Q36208986 | Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis |
Q26741152 | Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives |
Q58795392 | Mineralocorticoid receptor blockade for renoprotection |
Q38161538 | Mineralocorticoid receptor modulators: a patent review (2007 - 2012). |
Q90626583 | Mitigating risk of aldosterone in diabetic kidney disease |
Q88711774 | Neurohormonal Blockade in Heart Failure |
Q38845433 | New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease |
Q90046724 | New Molecules for Treating Resistant Hypertension: a Clinical Perspective |
Q38429870 | New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? |
Q34384580 | New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension |
Q38594785 | New medical therapies for heart failure |
Q38759494 | New pharmacological approaches in heart failure therapy: developments and possibilities. |
Q38225739 | Newest additions to heart failure treatment |
Q38658657 | Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. |
Q38349798 | Novel RAAS agonists and antagonists: clinical applications and controversies. |
Q38209074 | Novel drug mechanisms in development for heart failure |
Q38746316 | Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy. |
Q38192513 | Novel molecular angiotensin converting enzyme and angiotensin receptor imaging techniques |
Q50998627 | Outpatient management of chronic heart failure. |
Q53059504 | Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. |
Q88738876 | Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo |
Q51293660 | Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. |
Q47907201 | Pharmacologic Management for Heart Failure and Emerging Therapies |
Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
Q90473703 | Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease |
Q64100092 | Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments |
Q30251531 | Potential new drug treatments for congestive heart failure |
Q38384423 | Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). |
Q52688314 | Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. |
Q30248429 | Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney |
Q38287146 | Primary aldosteronism and salt |
Q90666788 | Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction |
Q34462504 | Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas |
Q89958002 | Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors |
Q26745900 | Recent advances in managing and understanding diabetic nephropathy |
Q38597498 | Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism |
Q38750210 | Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease |
Q26746907 | Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies |
Q101578601 | Role of mineralocorticoid receptor antagonists in kidney diseases |
Q38746216 | Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis |
Q38546917 | Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). |
Q38593070 | Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT? |
Q39199991 | Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside |
Q36514942 | Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. |
Q60153622 | The Renin-Angiotensin-Aldosterone System in Cardiovascular Diseases |
Q38168046 | The effect of RAAS blockade on the progression of diabetic nephropathy |
Q88551678 | The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction |
Q41677231 | The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. |
Q27013946 | The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series) |
Q38766590 | The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure |
Q52580660 | The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis. |
Q26996385 | Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease |
Q36437145 | Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth? |
Q38705827 | Treatment of Hyperkalemia in Heart Failure |
Q33907249 | Treatment of diabetic kidney disease: current and future targets |
Q47252893 | Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease |
Search more.